-

Urovant Sciences to Present at Cowen and Company’s 40th Annual Health Care Conference

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 5:40 a.m. Pacific / 8:40 a.m. Eastern on Tuesday, March 3, 2020, at Cowen and Company’s 40th Annual Health Care Conference in Boston.

A live, audio webcast for this event will be available on the Investor Relations section of the company’s website at http://ir.urovant.com. For those unable to listen to the live broadcast, a replay will be available for approximately 30 days on the company’s website.

About Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company’s lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist that is being evaluated for overactive bladder (OAB). Urovant Sciences reported positive data from the vibegron 12-week, Phase 3 pivotal EMPOWUR study and demonstrated favorable longer-term efficacy, safety, and tolerability in a 40-week extension study. The Company submitted a New Drug Application to the FDA seeking approval of vibegron for the treatment of patients with OAB in December 2019. Vibegron is also being evaluated for treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH) and for abdominal pain associated with irritable bowel syndrome (IBS). Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., which is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases. Learn more about us at www.urovant.com.

Contacts

Investor inquiries:
Ryan Kubota
949.769.2706
ryan.kubota@Urovant.com

Media inquiries:
Media@Urovant.com

Urovant Sciences

NASDAQ:UROV

Release Versions

Contacts

Investor inquiries:
Ryan Kubota
949.769.2706
ryan.kubota@Urovant.com

Media inquiries:
Media@Urovant.com

More News From Urovant Sciences

Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Options

IRVINE, Calif. & ZUG, Switzerland--(BUSINESS WIRE)--Urovant Sciences partners with actress and overactive bladder (OAB) patient Holly Robinson Peete as part of its Time To Go™ campaign....

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educational campaign in partnership with Thinx Inc., the leading period and incontinence underwear brand. This campaign highlights the impact of overactive bladder (OAB) and introduces options for managing symptoms of OAB, which may make those suffering from OAB feel more comfortable leaving their home this tr...

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the recent publication of a Phase 1 study of the pharmacokinetic profile of GEMTESA (vibegron) 75mg in the peer-reviewed journal, Clinical Pharmacology in Drug Development. In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce. The results suggest that crush...
Back to Newsroom